Drug intelligence / Profile preview

cecropin B

Development stage: Unknown
Modality: Peptides
Administration: Intraperitoneal, Intravenous

Overview

Cecropin B is a 35-amino acid cationic antimicrobial peptide derived from the giant silk moth, *Hylphora cecropia*. It functions as an antibacterial and anti-cancer agent by disrupting bacterial and cancerous cell membranes. Cecropin B has a helix-hinge-helix structure, which allows it to interact with microbial membranes, leading to cell death. It exhibits low cytotoxicity against mammalian cells, making it a potential therapeutic agent.

Targets

CM (Bacterial cytoplasmic membrane (Gram-negative))

Beyond the preview

Go deeper on cecropin B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cecropin B.

Explore the full profile